Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Sponsor: Sylentis, S.A.
This PHASE3 trial investigates Dry Eye Disease and Sjögren Syndrome and is currently completed. Sylentis, S.A. leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Mar 2023 — Mar 2024 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Oct 2021 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jun 2021 — Oct 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sylentis, S.A.
For direct contact, visit the study record on ClinicalTrials.gov .